

University of Groningen

Experimental studies on signal transduction pathways in rheumatoid arthritis

Bijl-Westra, Johanna

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2005

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Bijl-Westra, J. (2005). *Experimental studies on signal transduction pathways in rheumatoid arthritis*. s.n.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

LIST OF PUBLICATIONS

Westra J, Kułdo JM, van Rijswijk MH, Molema G and Limburg PC. Chemokine production and E-selectin expression in activated endothelial cells are inhibited by p38 MAPK (mitogen activated protein kinase) inhibitor RWJ 67657. *Int Immunopharmacol.* 2005, in press.

Westra J, Limburg PC, de Boer P, van Rijswijk MH. Effects of RWJ 67657, a p38 mitogen activated protein kinase (MAPK) inhibitor, on the production of inflammatory mediators by rheumatoid synovial fibroblasts. *Ann Rheum Dis.* 2004;63(11):1453-9.

Westra J, Doornbos-van der Meer B, de Boer P, van Leeuwen MA, van Rijswijk MH, Limburg PC. Strong inhibition of TNF-alpha production and inhibition of IL-8 and COX-2 mRNA expression in monocyte-derived macrophages by RWJ 67657, a p38 mitogen-activated protein kinase (MAPK) inhibitor. *Arthritis Res Ther.* 2004;6(4):R384-92.

Posthumus MD, Limburg PC, **Westra J**, van Leeuwen MA, van Rijswijk MH. Serum matrix metalloproteinase 3 levels in comparison to C-reactive protein in periods with and without progression of radiological damage in patients with early rheumatoid arthritis. *Clin Exp Rheumatol.* 2003 Jul-Aug;21(4):465-72.

Posthumus MD, Limburg PC, **Westra J**, van Leeuwen MA, van Rijswijk MH. Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis. *J Rheumatol.* 2002 May;29(5):883-9.

Posthumus MD, Limburg PC, **Westra J**, van Leeuwen MA, van Rijswijk MH. Serum matrix metalloproteinase 3 in early rheumatoid arthritis is correlated with disease activity and radiological progression. *J Rheumatol.* 2000 Dec;27(12):2761-8.

Posthumus MD, Limburg PC, **Westra J**, Cats HA, Stewart RE, van Leeuwen MA, van Rijswijk MH. Serum levels of matrix metalloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis. *Rheumatology (Oxford).* 1999 Nov;38(11):1081-7.

van Leeuwen MA, **Westra J**, Limburg PC, van Riel PL, van Rijswijk MH. Clinical significance of interleukin-6 measurement in early rheumatoid

arthritis: relation with laboratory and clinical variables and radiological progression in a three year prospective study.
Ann Rheum Dis. 1995 Aug;54(8):674-7.

van Leeuwen MA, **Westra J**, Limburg PC, van Riel PL, van Rijswijk MH.
Interleukin-6 in relation to other proinflammatory cytokines, chemotactic activity and neutrophil activation in rheumatoid synovial fluid.
Ann Rheum Dis. 1995 Jan;54(1):33-8.

van Leeuwen MA, **Westra J**, van Riel PL, Limburg PC, van Rijswijk MH.
IgM, IgA, and IgG rheumatoid factors in early rheumatoid arthritis predictive of radiological progression?
Scand J Rheumatol. 1995;24(3):146-53.

van Leeuwen MA, **Westra J**, Limburg PC, de Jong HJ, Marrink J, van Rijswijk MH.
Quantitation of IgM, IgA and IgG rheumatoid factors by ELISA in rheumatoid arthritis and other rheumatic disorders.
Scand J Rheumatol Suppl. 1988;75:25-31.

Kallenberg CG, Klaassen RJ, **Westra J**, Beelen JM, Ockhuizen T.
Immunoglobulin genes, HLA-B8/DR3, and immune responsiveness to primary immunogen and mitogens in normal subjects.
Clin Immunol Immunopathol. 1988 Jun;47(3):333-42.

van Leeuwen MA, van Rijswijk MH, **Westra J**, de Jong HJ, Marrink J.
[C-reactive protein; an expensive sedimentation?]
Ned Tijdschr Geneesk. 1986 Aug 2;130(31):1391-5. Dutch.

Beukhof JR, Ockhuizen T, Halie LM, **Westra J**, Beelen JM, Donker AJ, Hoedemaeker PJ, van der Hem GK.
Subentities within adult primary IgA-nephropathy.
Clin Nephrol. 1984 Oct;22(4):195-9.

Ockhuizen T, Beukhof JR, **Westra J**, Halie LM, Beelen JM, van der Hem GK.
Immunogenetic differences in subpopulations of patients with IgA nephropathy (Berger's disease).
Exp Clin Immunogenet. 1984;1(3):121-8.

Ockhuizen T, **Westra J**, Aalders JG, de Bruijn HW.
Immunoglobulin allotypes in patients with epithelial ovarian cancer.
Exp Clin Immunogenet. 1984;1(4):189-92.